Intrinsic resistance mechanisms to mutant KRAS specific inhibitor in KRAS mutated colorectal cancer

被引：0
|
作者：
Maruyama, Kohei [1 ,2 ]
Suzuki, Mai [1 ,2 ]
Ohhara, Tomoko [1 ]
Nagayama, Satoshi [3 ]
Fujita, Naoya [4 ]
Katayama, Ryohei [1 ,2 ]
机构：
[1] JFCR, Div Exp Chemother, Canc Chemother Ctr, Tokyo, Japan
[2] Univ Tokyo, Dept CBMS, Grad Sch Front Sci, Tokyo, Japan
[3] JFCR, Canc Inst Hosp, Dept Surg Gastroenterol, Tokyo, Japan
[4] JFCR, Canc Chemother Ctr, Tokyo, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-2032
引用
收藏
页码：783 / 783
页数：1
相关论文
共 50 条
  • [21] MicroRNA signature associated with KRAS-mutated colorectal cancer
    Andreoiu, O-M
    Dobre, M.
    Pirvu, I-R
    Vasilescu, F.
    Herlea, V.
    Becheanu, G.
    VIRCHOWS ARCHIV, 2017, 471 : S161 - S162
  • [22] THE ROLE OF ASPARAGINE SYNTHETASE IN COLORECTAL CANCER WITH MUTATED KRAS.
    Toda, K.
    Kawada, K.
    Iwamoto, M.
    Inamoto, S.
    Hasegawa, S.
    Sakai, Y.
    DISEASES OF THE COLON & RECTUM, 2017, 60 (06) : E117 - E118
  • [23] Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
    Adachi, Yuta
    Kimura, Ryo
    Hirade, Kentaro
    Ebi, Hiromichi
    CANCERS, 2021, 13 (20)
  • [24] Targeting immunosuppressive mechanisms in KRAS mutant lung cancer
    Havel, Lauren Smith
    Gao, Dingcheng
    Daniel, Jennifer S.
    Altorki, Nasser K.
    Mittal, Vivek
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S23 - S24
  • [25] Acquired Resistance to Anti EGFR Therapy in Colorectal Cancer and Paracrine Protection by KRAS Mutated Cells
    Hobor, S.
    Misale, S.
    Crowley, E.
    Scala, E.
    Zanon, C.
    Di Nicolantonio, F.
    Bardelli, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 51 - 51
  • [26] Mutation specific mechanisms of resistance to oncogenic KRAS inhibition
    Barravecchia, Ivana
    Lasse-Opsahl, Emily
    Cavanaugh, Sophia
    Rober, Lily
    Baliira, Rachael
    Robotti, Marzia
    Hinshaw, Rachael
    Lee, Jennifer M.
    Zhang, Yaqing
    di Magliano, Marina Pasca
    Galban, Stefanie
    CANCER RESEARCH, 2024, 84 (06)
  • [27] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [28] Advanced therapies on BRAF-mutated and KRAS-mutated metastatic colorectal cancer
    LI Zi-nan
    YU Li-feng
    WANG Jia-qi
    NIU Yan-xin
    WANG Xin-yu
    ZHAO Lin
    中国药理学与毒理学杂志, 2019, (10) : 883 - 883
  • [29] Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer
    Dimou, Anastasios
    Syrigos, Konstantinos
    Saif, Muhammad Wasif
    ANTI-CANCER DRUGS, 2011, 22 (05) : 384 - 391
  • [30] New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
    Prenen, Hans
    Tejpar, Sabine
    Van Cutsem, Eric
    CLINICAL CANCER RESEARCH, 2010, 16 (11) : 2921 - 2926
12345